글로벌 가려움증 약물 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

가려움증 약물 시장 분석

가려움증 약물 시장은 알레르기성 접촉 피부염 , 습진, 만성 피부 질환과 같은 가려움증 질환의 유병률 증가에 따라 상당한 성장을 목격하고 있습니다 . 글로벌 시장은 의료비 지출 증가와 치료 옵션에 대한 인식 제고로 인해 확대될 것으로 예상됩니다. 이 분야의 최근 발전에는 생물학적 제제 및 표적 치료와 같은 혁신적인 치료법이 도입되어 효능과 안전성 프로필이 개선되었습니다. 예를 들어 FDA가 가려움증 결절 및 중증 아토피 피부염 치료를 위한 단일 클론 항체인 네몰리주맙을 승인한 것은 가려움증 관리에 있어 상당한 진전을 의미합니다. 또한, 새로운 화합물과 복합 요법에 대한 지속적인 연구는 치료하기 어려운 가려움증 질환이 있는 환자의 치료 결과를 개선하는 것을 목표로 합니다. 더욱이 원격 진료 및 디지털 건강 솔루션의 확대는 피부과 치료에 대한 접근성을 개선하고 가려움증의 시기적절한 진단 및 치료를 용이하게 하여 궁극적으로 시장 확장을 촉진하고 있습니다.

가려움증 약물 시장 규모

글로벌 가려움증 약물 시장 규모는 2023년에 76억 1,000만 달러로 평가되었으며, 2031년까지 1,13억 2,000만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 5.10%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

가려움증 약물 시장 동향

“ 생물학적 제제 사용 증가”

글로벌 가려움증 약물 시장은 만성 피부 질환의 유병률 증가와 치료 옵션에 대한 인식 증가에 영향을 받아 상당한 성장을 경험하고 있습니다. 주목할 만한 추세 중 하나는 아토피성 피부염 및 건선 과 같은 질환과 관련된 가려움증을 관리하는 데 점점 더 많이 사용되는 생물학적 제제로의 전환입니다 . 예를 들어, Dupilumab과 같은 약물은 가려움증을 완화하고 피부 상태를 개선하는 데 유망한 결과를 보였습니다. 또한 원격 진료의 확대로 환자가 피부과 상담에 더 쉽게 접근할 수 있어 시기적절한 진단 및 치료 계획이 용이해지고 있습니다. 이러한 추세는 환자에게 권한을 부여하고 개인화된 의료 솔루션에 대한 증가하는 수요와 일치하기 때문에 중요합니다. 고급 치료법과 환자 중심적 접근 방식을 통합함으로써 가려움증 약물 시장은 강력한 확장을 준비하고 있으며, 충족되지 않은 요구를 해결하고 가려움증 관련 질환으로 고통받는 수백만 명의 삶의 질을 개선할 준비가 되어 있습니다.

보고서 범위 및 가려움증 약물 시장 세분화         

Pruritus Drug Market Definition

Pruritus drugs are medications specifically designed to alleviate itching (pruritus) caused by various conditions, including allergic reactions, skin disorders, and underlying systemic diseases. These drugs work through different mechanisms to reduce the sensation of itch and provide relief. Common classes of drugs for pruritus include antihistamines, which block histamine receptors to prevent allergic responses; corticosteroids, which reduce inflammation and immune response; and topical agents, such as calamine or menthol, which provide cooling effects. By targeting the underlying causes or symptoms of pruritus, these medications aim to improve patient comfort and quality of life.

Pruritus Drug Market Dynamics

Drivers

• Growing Aging Population

The aging population is significantly influencing the pruritus drug market, as older adults are more prone to skin conditions that lead to itching and discomfort. According to the United Nations, by 2030, the number of individuals aged 60 and older is projected to reach 1.4 billion, representing a substantial increase from 1 billion in 2019. Such demographic shift is critical, as age-related skin changes, such as reduced skin barrier function and chronic conditions like xerosis (dry skin), make older adults particularly susceptible to pruritus. For instance, studies show that older adults who experiences pruritus, their quality of life get severely impacted and lead to further complications, including skin infections and sleep disturbances. Consequently, the demand for specialized treatments that address the unique needs of this age group is increasing, consequently driving the market growth.

• Increasing Prevalence of Chronic Skin Disorders

The increasing prevalence of chronic skin disorders, including atopic dermatitis, psoriasis, and eczema, serves as a crucial market driver for the pruritus drug market, significantly boosting the demand for effective management solutions. The World Health Organization (WHO) reports that skin disorders affect nearly 900 million people globally, representing approximately 30% of the global population at some point in their lives. Specifically, atopic dermatitis affects 20% of children and up to 10% of adults worldwide, particularly in urban areas. In parallel, psoriasis impacts around 125 million people globally, often leading to severe itching and discomfort. This growing burden of skin disorders highlights the urgent need for innovative treatments and management strategies. As a result, pharmaceutical companies are increasingly focusing on developing targeted therapies that not only alleviate pruritus but also enhance the overall quality of life for affected individuals, making chronic skin conditions a significant driver of growth in the pruritus drug market.

Opportunities

• Rising Advancements in Targeted Therapies

Advancements in targeted therapies have revolutionized the treatment landscape for chronic pruritus by enabling more precise interventions that address specific underlying causes of itching. For instance, the introduction of IL-31 receptor antagonists, such as nemolizumab, has shown promising results in clinical trials, with studies indicating a significant reduction in pruritus in patients with atopic dermatitis compared to placebo. Such advancements enhances treatment efficacy and safety and  aligns with the broader trend of personalized medicine, offering tailored approaches to individual patients based on their specific conditions and responses to treatment. As a result, broadening market opportunities.

• Increasing Frequency of Special Designations from Regulatory Authorities

The global pruritus drug market is poised for significant growth, bolstered by the increasing frequency of special designations from regulatory authorities. Initiatives such as the FDA's Orphan Drug Designation and Breakthrough Therapy Designation are accelerating the development of new therapies targeting pruritus. For instance, the FDA granted Breakthrough Therapy Designation to Dupilumab for the treatment of pruritus associated with atopic dermatitis, recognizing its potential to provide significant improvements over existing treatments. Such designation not only expedites the drug's development and review process but also encourages investment in research and development by pharmaceutical companies. As regulatory bodies continue to support the development of novel treatments, the pruritus drug market stands to benefit from enhanced patient access to effective therapies, creating further opportunities in the pruritus drug market.

Restraints/Challenges

• High Treatment Costs

High treatment costs represent a significant challenge for the global pruritus drug market, potentially limiting patient access to effective therapies. The rising prices of innovative treatments, particularly biologics, can create barriers for patients and healthcare systems. For instance, the annual cost of Dupilumab, a leading biologic for treating pruritus associated with atopic dermatitis, can exceed several thousand USD in the United States, making it unaffordable for many patients without adequate insurance coverage, thereby making high treatment costs a critical market challenge within the pruritus drug sector.

• Patent Expiration of Branded Drugs

The patent expiration of branded drugs poses a considerable challenge to the global pruritus drug market, as it leads to the introduction of generic versions that can significantly alter market dynamics. When patents expire, generic manufacturers can produce lower-cost alternatives, which often results in reduced revenue for original brand-name drug manufacturers. For instance, the patent for Dupilumab is set to expire in 2028, paving the way for generic competitors that could offer similar efficacy at a fraction of the cost. In addition, the introduction of generics may dilute brand loyalty and complicate patient access to established therapies, particularly if the generic versions do not match the original in terms of efficacy or safety. Therefore, the patent expirations and subsequent rise of generics present significant challenges for maintaining revenue growth and innovation within the pruritus drug market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Pruritus Drug Market Scope

The market is segmented on the basis of types, drugs, route of administration, end users, and distribution channels. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Chronic Kidney Disease associated Pruritus
• Chronic Liver Disease associated Pruritus
• Atopic Dermatitis Associated Pruritus
• Others

Drugs

• Corticosteroids
• Antihistamines
• Counterirritants
• Others

Route of Administration

• Injectable
• Topical
• Oral
• Others

End Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retailers
• Others

Pruritus Drug Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, types, drugs, route of administration, end users, and distribution channels as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the market primarily due to its robust healthcare infrastructure, which supports the adoption of advanced medical technologies. In addition, the region is witnessing an increasing prevalence of hematologic diseases, driving demand for effective treatment solutions. This combination of infrastructure and rising health concerns positions North America as a key player in the market.

The Asia-Pacific region is expected to achieve the highest growth rate and demonstrate the strongest compound annual growth rate (CAGR) during the forecast period. This growth can be attributed to increasing investments in healthcare infrastructure development, a rising incidence of allergic contact dermatitis and urticaria, and growing awareness of available treatment options. These factors collectively contribute to a favorable environment for the expansion of healthcare services and products in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Pruritus Drug Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Pruritus Drug Market Leaders Operating in the Market Are:

• AbbVie Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• 암젠 주식회사(미국)
• 파이저 주식회사(미국)
• 카라 테라퓨틱스(미국)
• 엔테리스 바이오파마(미국)
• NeRRe Therapeutics (영국)
• Vyne Therapeutics Inc. (미국)
• XBiotech USA, Inc. (미국)
• Ipsen Pharma(프랑스)
• Eledon Pharmaceuticals, Inc. (미국)
• 아모레퍼시픽(한국)
• RDD Pharma, Ltd. (이스라엘)
• 노바티스 AG(스위스)
• 아스트라제네카(영국)
• 사노피(프랑스)
• Sun Pharmaceutical Industries Ltd. (인도)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• 다케다제약 주식회사(일본)

가려움증 약물 시장의 최신 동향

• 2024년 2월, Galderma는 미국 식품의약국(FDA)이 네몰리주맙에 대한 생물학적 제제 허가 신청을 수락했다고 발표했습니다. 이 신청은 가려움증(prurigo nodularis) 치료와 중증에서 중증의 아토피 피부염이 있는 청소년 및 성인을 대상으로 합니다.
• 2023년 9월, 바이오제약 회사인 Cara Therapeutics, Inc.는 라이선스 파트너인 Maruishi Pharmaceutical Co., Ltd.가 일본 후생노동성으로부터 KORSUVA IV 주사 주사기의 제조 및 마케팅에 대한 승인을 받았다고 발표했습니다. 이 승인은 특히 혈액 투석을 받는 환자의 가려움증을 치료하기 위한 것으로, 이 질환의 관리에 있어 주목할 만한 진전을 나타냅니다.

SKU-46133